Lung Cancer research lines

Reading time: 2 min

Clinical trials
Several different treatments aimed at each type of cancer are currently being studied. Clinical trials are necessary to complete an objective and controlled evaluation of the activity of the drugs in question. Many of these treatments are still not authorised for indication in a healthcare setting and so clinical trials represent a unique opportunity for patients to potentially benefit from these new therapies.

If you wish to obtain specific information about clinical trials and therapies under investigation, you should ask your doctor to find out whether you can participate in one of them.

Molecular markers
The most important development in recent years has undoubtedly been the identification of molecular markers that can be used to predict each individual’s response to treatments other than chemotherapy.

Advances in molecular diagnostics and targeted therapies provide glimpses of an optimistic future for lung cancer. It is known that up to 60% of lung adenocarcinomas may, in the future, be treatable with targeted molecular therapy. To achieve this end, the tumour must be analysed with high-precision technologies that identify the intracellular mechanisms characteristic of the tumour.

Over the coming years, new targeted gene therapies will be available for lung carcinomas; these treatments will be associated with less toxicity and greater antitumour efficacy.

Biomarkers
The analysis of biomarkers in the tumour tissue helps us decide which drugs are the most appropriate and effective for each patient. For example, the subgroup of patients with lung adenocarcinoma standout because they carry a mutation in the epidermal growth factor receptor (EGFR) gene; there are already drugs available that can block the mutation and consequently inhibit tumour growth.

The ALK gene is also known to undergo a mutation and again drugs are already available to target this variation. Other biomarkers proven to predict patient response to targeted treatments are ROS, BRAF and c-Met.

Early detection
In contrast to other tumours, e.g., breast, colon or cervical cancer, the role of early detection of lung cancer in at-risk populations such as smokers or ex-smokers is still unclear. Radiography does not provide enough sensitivity as an early detection method for lung cancer.

A study in the USA has demonstrated that CT imaging offers benefits as an early detection method in at-risk populations. However, these screening programs are not routinely established in Europe. Several studies are currently underway to validate the results of the American study. Early detection will undoubtedly improve the cure rates for lung cancer.

Substantiated information by:
Ramon Mª MarradesPneumologist — Pneumology DepartmentLaureano MolinsThoracic Surgeon — Thoracic Surgery DepartmentNoemí ReguartOncologist — Oncology DepartmentMari Carmen RodríguezNurse — Oncology DepartmentDavid SánchezThoracic Surgeon — Thoracic Surgery DepartmentNúria ViñolasOncologist — Oncology Department

Published: 20 February 2018
Updated: 20 February 2018

Subscribe

Receive the latest updates related to this content.

Thank you for subscribing!

We have received your information. Check your inbox, in a few moments you will receive a confirmation email.

An error occurred and we were unable to send your data, please try again later.